Collaborative Pilot Projects
The ARTNet RFA-CA-21-052 mandated “Restricted Funds”. This specified that each U54 budget should include funds (15% of the overall ARTNet Center budget) for trans- or extra-ARTNet collaborative pilot projects (CPPs) for years 2-5.
Year 2
| Number | Title | Collaborators |
|---|---|---|
| 1 | Metabolic targeting of platinum resistance in humanized models of head and neck cancer | ARTI-U54 BAATAAR-UP U54 H-CARR U54 |
| 2 | Characterizing metabolomic changes during acquired radioresistance in pancreatic cancer | ARTI-U54 PCAC U54 |
| 3 | Selectively poisoning oncogenic transcription with CHROMAtin TArgeting Chimeras (CHROMATACs) to address cancer therapy resistance" | BAATAAR-UP
U54 External member: Dr. Jonathan Ostrem |
| 4 | Imaging Metabolic Alterations Related to Treatment in Lung Cancer | BAATAAR-UP
U54 H-CARR U54 |
| 5 | Improving AI/ML readiness of ARTNET data to serve as a catalyst for trans-network modeling | OHSU U54 CDMC-U24 |
| 6 | Transcriptional and epigenetic states in PD-1 resistance in a model of AML | OHSU U54 CDMC-U24 |
Year 3 - 2024
| Number | Title | Collaborators |
|---|---|---|
| 1 | Leveraging Exosome Molecular Profiling for Predictive Monitoring and Treatment Optimization in Solid Tumors | ARTI-U54 H-CARR U54 |
| 2 | Characterizing metabolomic changes during acquired radioresistance in pancreatic cancer | ARTI-U54 PCAC U54 |
| 3 | Selectively poisoning oncogenic transcription with CHROMAtin TArgeting Chimeras (CHROMATACs) to address cancer therapy resistance" | BAATAAR-UP
U54 External member: Dr. Jonathan Ostrem |
| 4 | Small molecule inhibitors of APOBEC3A/B to prevent mutational resistance in lung cancer. | BAATAAR-UP
U54 External member: Dr. Jonathan Ostrem |
| 5 | Dissecting Transcriptomic and Epigenetic Mechanisms of Venetoclax Resistance in AML at single cell level | OHSU U54 CDMC-U24 |
| 6 | Combatting Acquired Resistance to CDK4/6 Inhibitors in AML and Solid Tumors | AML - OHSU U54 CDMC-U24 |
| 7 | Evaluating the ability of ferroptosis inducers to radiosensitize Keap1-deficient head and neck cancer using a genetically engineered mouse model | ARTI-U54 H-CARR U54 |
Year 4 - 2025
| Number | Title | Collaborators |
|---|---|---|
| 1 | Studying and Targeting Radioresistance in Lung Cancer | ARTI-U54 BAATAAR-UP U54 |
| 2 | Characterizing metabolomic changes during acquired radioresistance in pancreatic cancer | ARTI-U54 PCAC U54 |
| 3 | Small molecule inhibitors of APOBEC3A/B to prevent mutational resistance in lung cancer. | BAATAAR-UP
U54 External member: Dr. Jonathan Ostrem |
| 4 | Investigating metabolic adaptations during targeted therapy resistance in lung cancer | BAATAAR-UP
U54 PCAC U54 |
| 5 | Tracking Cancer Associated Macrophage-Like (CAML) Cells to Assess OPSCC Response to Therapy (**Has Human Subject Study: ASSIST ID: 1264797) | H-CARR U54 ARTI-U54 |
| 6 | Characterizing the potential of endogenous anti-tumor T-cell immunity in NRF2 hyperactivated head and neck tumors | H-CARR U54 CDMC-U24 |
| 7 | Combatting Acquired Resistance to CDK4/6 Inhibitors in AML and Solid Tumors | OHSU U54 CDMC-U24 |
| 8 | Identifying mechanisms of drug resistance in AML by using spatial Multi-Omics profiling | OHSU U54 ARTI-U54 |
